Key Takeaways
Merck & Co. (NYSE: MRK) shares gained 4 percent in pre-market trading after the company announced on April 30 that its first-quarter sales exceeded analyst expectations, indicating robust demand for its key pharmaceutical products.
"Our strong start to 2026 reflects robust demand for our key oncology and vaccine products, positioning us for continued growth," a company representative said in a statement.
The company’s sales surpassed the consensus revenue estimate of $15.9 billion, which analysts had projected would be a 2.4 percent increase from the prior year. The consensus earnings per share estimate for the quarter stood at a loss of $1.51. While Merck confirmed a beat on revenue, the specific top and bottom-line figures were not immediately disclosed.
The positive result reinforces Merck's reliance on its high-growth oncology division to drive performance. Ahead of the report, analysts projected sales for the blockbuster cancer drug Keytruda would reach $7.73 billion for the quarter. The firm's partnership with AstraZeneca on the cancer drug Lynparza was also projected to contribute $149.7 million in alliance revenue in the U.S.
Wall Street also anticipated continued growth from other areas of Merck's portfolio. Sales for the cancer treatment Welireg were forecast at $192.28 million, representing 40.4 percent year-over-year growth. The animal health division was expected to contribute $1.67 billion, up 5.4 percent from the year-ago quarter.
The strong earnings beat provides Merck with positive momentum as it navigates an environment of increasing competition and upcoming patent expirations. Investors will be looking for further details on the performance of key growth drivers and any updates to the company's full-year guidance in the upcoming investor call.
This article is for informational purposes only and does not constitute investment advice.
